This is a pre-market, prospective, randomized (2:1), multicenter, multi-national pivotal
clinical investigation. The purpose of this investigation is to determine the clinical safety
and performance of GATT-Patch as compared with TachoSil for the management of minimal, mild,
or moderate bleeding during elective open liver surgery.